Twist Bioscience (TWST) Stock
Key stats
- Market cap
- $7.04B
- Price / Earnings ratio
- -58.4x
- EPS (TTM)
- -$2.08
- Volume
- Loading
- 52-week high
- $219.71
- 52-week low
- $25.67
- EPS vs analyst estimate
- +2.2%Q4 FY25 · -$0.45 vs -$0.46
Source: third-party data provider, as of November 22, 2026
EPS estimate: analyst consensus
Compare with TWST
Recent news

Cathie Wood Boosts Bets On 2 AI Firms Amid Nvidia’s Huang Upheaval — Here’s How Her Trading Week Unfolded
Cathie Wood Boosts Bets On 2 AI Firms Amid Nvidia’s Huang Upheaval — Here’s How Her Trading Week Unfolded
TWST

Twist Bioscience Q4 Earnings Call Highlights
Twist Bioscience Q4 Earnings Call Highlights
TWST

Twist Bioscience: 3 Key Takeaways for Long-Term Investors
Twist Bioscience: 3 Key Takeaways for Long-Term Investors
TWST

Twist Bioscience (TWST) Reports Q4 Loss, Beats Revenue Estimates
Twist Bioscience (TWST) Reports Q4 Loss, Beats Revenue Estimates
TWST
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 37.10
- MACD 12/26/9
- -11.40
- EMA 9 of MACD
- -9.40
- MACD histogram
- -2.00
- SMA 50
- $148.55
- Price below SMA 50
- EMA 50
- $135.01
- Price below EMA 50
- SMA 200
- $94.83
- Price above SMA 200
- EMA 200
- $98.01
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 20, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
Source: third-party data provider
Latest news

Cathie Wood Boosts Bets On 2 AI Firms Amid Nvidia’s Huang Upheaval — Here’s How Her Trading Week Unfolded
Cathie Wood Boosts Bets On 2 AI Firms Amid Nvidia’s Huang Upheaval — Here’s How Her Trading Week Unfolded
TWST

Twist Bioscience Q4 Earnings Call Highlights
Twist Bioscience Q4 Earnings Call Highlights
TWST

Twist Bioscience: 3 Key Takeaways for Long-Term Investors
Twist Bioscience: 3 Key Takeaways for Long-Term Investors
TWST

Twist Bioscience (TWST) Reports Q4 Loss, Beats Revenue Estimates
Twist Bioscience (TWST) Reports Q4 Loss, Beats Revenue Estimates
TWST

This Biotech's Guidance Seemingly Beat Expectations — But A Twist Slammed The Stock
This Biotech's Guidance Seemingly Beat Expectations — But A Twist Slammed The Stock
TWST

Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results
Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results
TWST

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
TWST

Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
TWST

Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
TWST

Notice of Proposed Derivative Settlement: Twist Bioscience Corporation
Notice of Proposed Derivative Settlement: Twist Bioscience Corporation
TWST
News tone: automated (AI) classification of the article's content, not a price prediction.
About Twist Bioscience
At Twist Bioscience, we work in the service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Emily Marine Leproust Ph.D. | Co-Founder, Board Chair & CEO | 1973 |
| Dr. Patrick John Finn Ph.D. | President & COO | 1972 |
| Mr. Adam Laponis | Chief Financial Officer | 1977 |
| Mr. Dennis Cho J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
| Ms. Paula Green | Senior Vice President of Human Resources | 1968 |
| Mr. Robert F. Werner | VP & Chief Accounting Officer | 1973 |
| Mr. Siyuan Chen | Chief Technology Officer | — |
| Dr. Michael Fero Ph.D. | Chief Information Officer | — |
| Dr. Colby Souders Ph.D. | Chief Scientific Officer | — |
| Ms. Nicole Moreno | Senior Vice President of Sales & Support | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 22, 2026
Technical indicators
- RSI 14
- 37.10
- MACD 12/26/9
- -11.40
- EMA 9 of MACD
- -9.40
- MACD histogram
- -2.00
- SMA 50
- $148.55
- Price below SMA 50
- EMA 50
- $135.01
- Price below EMA 50
- SMA 200
- $94.83
- Price above SMA 200
- EMA 200
- $98.01
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 20, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $45.00
- Average
- $142.00
- High
- $212.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.2 | -11.1 | ||||||||||
| 2022 | -28.6 | -10.3 | -11.0 | -45.5 | +8.6 | +13.1 | +18.0 | -10.1 | -12.9 | -9.0 | -19.0 | -14.5 |
| 2023 | +20.5 | -33.1 | -17.6 | -11.4 | +22.5 | +27.8 | +22.6 | -3.9 | -14.0 | -17.8 | +54.0 | +48.7 |
| 2024 | -6.5 | +18.1 | -11.8 | -9.2 | +31.1 | +12.0 | +14.1 | -18.5 | +10.3 | -7.0 | +18.3 | -7.6 |
| 2025 | +15.6 | -26.4 | +5.8 | -1.6 | -22.3 | +18.4 | -8.7 | -19.9 | +7.2 | +12.4 | +1.4 | +6.2 |
| 2026 | +26.8 | +0.2 | +3.6 | +18.0 | +10.7 | +51.6 | -10.5 | +37.5 | +46.3 | -18.8 | -19.9 |



